Topics

Companies Related to "GITR agonism exploited combination with checkpoint blockade overcome" [Most Relevant Company Matches] RSS

11:12 EDT 21st September 2019 | BioPortfolio

Here are the most relevant search results for "GITR agonism exploited combination with checkpoint blockade overcome" found in our extensive corporate database of over 50,000 company records.

Showing "GITR agonism exploited combination with checkpoint blockade overcome" Companies 1–25 of 134

Relevant

Checkpoint Surgical, Inc.

Checkpoint Surgical is a privately held, Cleveland, Ohio based medical device company committed to providing surgeons with user-friendly, cost-effective devices to protect and repair nerve intraoperatively across the anatomy. At Checkpoint Surgical, our mission is to advance the science and practice of nerve protection and repair to improve the quality of ...


Agenus, Inc.

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® is used to generate fully human therapeutic antibody drug c...

Blockade Medical

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and neurovascular disease. The company manufactures the Barricade Coil System and is based in Irvine, California.


Blockade Medical LLC

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and related disease of the neurovascular system. The company manufactures the Barricade Coil System in The United States and is based in Irvine, California.

Checkpoint Systems, Inc.

Checkpoint Systems is a global leader in merchandise availability solutions for the retail industry, encompassing loss prevention and merchandise visibility. Checkpoint provides end-to-end solutions enabling retailers to achieve accurate real-time inventory, accelerate the replenishment cycle, prevent out-of-stocks and reduce theft, thus improving merchand...

Blockade Medical L.L.C.

Blockade Medical is a privately held medical device company focused on expanding the endovascular management of hemorrhagic stroke and related disease of the neurovascular system. The company manufactures the Barricade Coil System in The United States and is based in Irvine, California.

ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobuli...

Alexo Therapeutics

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin....

National Center for Missing & Exploited Children

Checkpoint Systems

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...

Probably Relevant

Epilepsy Foundation of Georgia

The Epilepsy Foundation, a national nonprofit with affiliated organizations throughout the United States, has lead the fight since 1968 to stop seizures, find a cure and overcome the challenges created by epilepsy. For additional information, please visit www.epilepsyfoundation.org.

Heartbeat Digital

Founded in 1998, Heartbeat is the digitally native, full service, Consumer & HCP AOR leader with a unique focus on Challenger Brands. Challengers are brands that are breaking new ground or entering highly competitive environments and thus need a decidedly different approach to breakthrough and have market impact. We help brands overcome the odds and exceed...

GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and ...

Allecra Therapeutics GmbH

Allecra Therapeutics Allecra is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra’s Mission Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving ...

Remedios Limited

Remedios is a forward-looking and award-winning environmental biotechnology company which was spun out of the University of Aberdeen in 1999. Remedios has successfully exploited the commercial opportunities arising from unique biosensor technology developed within the University. The biosensor technology is used in conjunction with traditional site investigations and environmental risk assessments...

Galecto Biotech AB

Galectin-3 is a member of the galectin family of galactoside binding lectins. Galectin-3 exists both intra- and extracellularly and binds to glycosylated proteins. Galectin-3 has been shown to play a central role in fibrosis development and progression. The activation of macrophages, and recruitment and activation of myofibroblasts, the two central cell ty...

Codenomicon

Codenomicon finds security vulnerabilities others can't find. Companies rely on Codenomicon's solutions to discover zero-day vulnerabilities that cause Denial of Service (DoS) and data leakage if exploited by hackers -- the unknown vulnerabilities Advanced Persistent Threats (APTs) use to break into systems. Codenomicon's customers include Alcatel-Lucent, ...

TILT Biotherapeutics Ltd

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy (including checkpoint antibodies) with oncolytic viruses. The company’s patented technology is uniquely based on human observations on the effect of oncolytic adenoviruses on the adaptive immune system. www.tiltbio.com

Sg2

Sg2, a Vizient company, enables health care executives to make better, faster, more cost-effective strategic decisions through a unique combination of industry leading market analytics and unrivaled expertise. Visit Sg2.com for more information.

Tau Therapeutics LLC

Tau Therapeutics is a clinical stage company developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel – a novel mechanism of action for cancer. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type ...

AVEO Oncology & Astellas Pharma Inc.

In February 2011, AVEO and Astellas entered into a worldwide agreement to develop and commercialize tivozanib outside of Asia for the treatment of a broad range of cancers. Tivozanib, AVEO's lead investigational drug, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimi...


More From BioPortfolio on "GITR agonism exploited combination with checkpoint blockade overcome"

Quick Search

Corporate Database Quicklinks